Kim Van der Eecken
Overview
Explore the profile of Kim Van der Eecken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
290
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Deek M, Mendes A, Song Y, Shetty A, Bazyar S, et al.
Radiother Oncol
. 2024 Nov;
202:110618.
PMID: 39510141
Background: There is a need for clinically actionable prognostic and predictive tools to guide the management of oligometastatic castration-sensitive prostate cancer (omCSPC). Methods: This is a multicenter retrospective study to...
2.
Sutera P, Song Y, Shetty A, English K, Van der Eecken K, Guler O, et al.
Eur Urol Oncol
. 2024 Jun;
8(1):111-118.
PMID: 38862340
Background And Objective: Oligometastatic castration-sensitive prostate cancer (omCSPC) represents an early state in the progression of metastatic disease for which patients experience better outcomes in comparison to those with higher...
3.
Warner E, Van der Eecken K, Murtha A, Kwan E, Herberts C, Sipola J, et al.
Nat Cancer
. 2024 Jan;
5(1):114-130.
PMID: 38177459
De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely collected tissue has hindered genomic stratification and precision oncology. Here, we leveraged a rare study of surgical...
4.
Hoang T, Sutera P, Nguyen T, Chang J, Jagtap S, Song Y, et al.
Prostate
. 2023 Oct;
84(1):87-99.
PMID: 37812042
Purpose: Despite well-informed work in several malignancies, the phenotypic effects of TP53 mutations in metastatic castration-sensitive prostate cancer (mCSPC) progression and metastasis are not clear. We characterized the structure-function and...
5.
Pizurica M, Larmuseau M, Van der Eecken K, de Schaetzen van Brienen L, Carrillo-Perez F, Isphording S, et al.
Cancer Res
. 2023 Jun;
83(17):2970-2984.
PMID: 37352385
Significance: Deep learning models predicting TP53 mutations from whole slide images of prostate cancer capture histologic phenotypes associated with stromal composition, lymph node metastasis, and biochemical recurrence, indicating their potential...
6.
Sutera P, Song Y, Van der Eecken K, Shetty A, English K, Hodges T, et al.
Eur Urol
. 2023 May;
84(6):531-535.
PMID: 37173210
In metastatic castration-sensitive prostate cancer (mCSPC), disease volume plays an integral role in guiding treatment recommendations, including selection of docetaxel therapy, metastasis-directed therapy, and radiation to the prostate. Although there...
7.
Sutera P, Deek M, Van der Eecken K, Shetty A, Chang J, Hodges T, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jan;
115(5):1095-1101.
PMID: 36708787
Purpose: WNT signaling is a cellular pathway that has been implicated in the development and progression of prostate cancer. Oligometastatic castration-sensitive prostate cancer (omCSPC) represents a unique state of disease...
8.
Deek M, Van der Eecken K, Sutera P, Deek R, Fonteyne V, Mendes A, et al.
J Clin Oncol
. 2022 Aug;
40(29):3377-3382.
PMID: 36001857
JCO The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes...
9.
Sutera P, Deek M, Van der Eecken K, Wyatt A, Kishan A, Molitoris J, et al.
Prostate
. 2022 Jun;
82 Suppl 1:S73-S85.
PMID: 35657158
Our ability to prognosticate the clinical course of patients with cancer has historically been limited to clinical, histopathological, and radiographic features. It has long been clear however, that these data...
10.
Fonseca N, Van der Eecken K, Herberts C, Verbeke S, Ng S, Lumen N, et al.
JCO Precis Oncol
. 2022 May;
6:e2100543.
PMID: 35507889
Purpose: Pulmonary involvement is rare in metastatic hormone-sensitive prostate cancer (mHSPC) that recurs after treatment for localized disease. Guidelines recommend intensive systemic therapy, similar to patients with liver metastases, but...